Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
UK: A recent study published in BMJ Medicine found that more caffeine in the blood can reduce the risk of type 2 diabetes and obesity. more...
Read Full NewsA nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.
The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.
Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.
REZOLVE-AD: Rezpegaldesleukin Improves Symptoms of Atopic Dermatitis
1.
COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment
2.
Implant-based reconstruction linked to increased risk of breast lymphomas
3.
Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.
4.
Fixed-Duration Oral Doublet for Fit CLL Wins in Frontline Setting
5.
November 2023, Medical Bulletin 04/.
1.
The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide
2.
Unravelling the Mysteries of Monoclonal Gammopathy
3.
Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Octreotide's Efficacy in Reducing Transfusion Requirements in Angiodysplasia Bleeding
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
5.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge